https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png 0 0 admin https://enterprisetherapeutics.com/wp-content/uploads/2018/05/Enterprise-Therapeutics-Logo-2.png admin2017-06-01 12:38:182018-05-11 12:38:42The discovery of potentiators of the calcium activated chloride channel, TMEM16A, oral communication at the Cystic Fibrosis Foundation Research Conference, Stevenson, USA, June 2017
You are here: Home1 / Publications2 / The discovery of potentiators of the calcium activated chloride channel,...
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical OfficerFebruary 8, 2022 - 8:00 am
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001June 14, 2021 - 9:00 am
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
Follow Us On Twitter
Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK.
Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases.
Learn more and register here: https://bit.ly/3X0Wh6P #COGUK
Sussex Innovation Centre,
University of Sussex,
Science Park Square,
Falmer, Brighton, BN1 9SB
+44 (0)1273 234667